**Table 2:** A Summary of Clinic Visits Characteristics

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Primary Disease  Site | Type of Clinic Visit | | | | | | | | | | |
| Radiation Clinic | Radiation Planning | Radiation Review Clinic | Radiation Treatment | Systemic Clinic | Systemic Treatment | Palliative Care Clinic | Psychosocial Onc. Clinic | Surgery Clinic | Minor Procedure | All |
| N (%) | | | | | | | | | | |
| Breast | 8395(4.2) | 2878(1.4) | 9331(4.6) | 13555(6.7) | 16264(8.1) | 11444(5.7) | 995(0.5) | 696(0.3) | 251(0.1) | 515(0.3) | 64324(31.9) |
| CNS | 91(\*) | 33(\*) | 131(0.1) | 191(0.1) | 357(0.2) | 156(0.1) | 29(\*) | 21(\*) | 2(\*) | 2(\*) | 1013(0.5) |
| Endocrine | 21(\*) | 6(\*) | 7(\*) | 11(\*) | 70(\*) | 35(\*) | 28(\*) | 2(\*) | 2(\*) | 4(\*) | 186(0.1) |
| GI | 2856(1.4) | 948(0.5) | 2767(1.4) | 4784(2.4) | 12837(6.4) | 5787(2.9) | 1521(0.8) | 1762(0.9) | 140(0.1) | 432(0.2) | 33834(16.8) |
| GU | 5132(2.5) | 824(0.4) | 2891(1.4) | 4027(2.0) | 3378(1.7) | 1138(0.6) | 683(0.3) | 198(0.1) | 82(\*) | 84(\*) | 18437(9.1) |
| GYN | 1297(0.6) | 198(0.1) | 702(0.3) | 1311(0.6) | 2512(1.2) | 915(0.5) | 296(0.1) | 154(0.1) | 86(\*) | 119(0.1) | 7590(3.8) |
| Haematology | 1453(0.7) | 552(0.3) | 1140(0.6) | 1834(0.9) | 24023(11.9) | 7997(4.0) | 1072(0.5) | 488(0.2) | 127(0.1) | 1694(0.8) | 40380(2\*) |
| H&N | 130(0.1) | 32(\*) | 76(\*) | 123(0.1) | 81(\*) | 24(\*) | 5(\*) | 23(\*) | 33(\*) | 4(\*) | 531(0.3) |
| Lung | 3560(1.8) | 1504(0.7) | 2018(1.0) | 4432(2.2) | 6274(3.1) | 2363(1.2) | 1466(0.7) | 505(0.3) | 1547(0.8) | 340(0.2) | 24009(11.9) |
| Sarcoma | 158(0.1) | 51(\*) | 57(\*) | 103(0.1) | 761(0.4) | 361(0.2) | 58(\*) | 50(\*) | 174(0.1) | 60(\*) | 1833(0.9) |
| Skin | 1637(0.8) | 347(0.2) | 939(0.5) | 1331(0.7) | 3680(1.8) | 434(0.2) | 38(\*) | 101(0.1) | 200(0.1) | 35(\*) | 8742(4.3) |
| Primary Unknown | 137(0.1) | 47(\*) | 62(\*) | 130(0.1) | 273(0.1) | 39(\*) | 37(\*) | 29(\*) | 50(\*) | 23(\*) | 827(0.4) |
| Other Cancers | 43(\*) | 7(\*) | 14(\*) | 23(\*) | 32(\*) | 4(\*) | 1(\*) | 9(\*) | - | - | 133(0.1) |
| All | 24910(12.3) | 7427(3.7) | 20135(10.0) | 31855(15.8) | 70542(34.9) | 30697(15.2) | 6229(3.1) | 4038(2.0) | 2694(1.3) | 3312(1.6) | 201839(100.0) |

\*=Value < 0.1%; CNS=Central Nervous System; H&N=Head and Neck; GI=Gastrointestinal; GU=Genitourinary; GYN=Gynaecological cancers

**Table 4a:** ESAS symptoms mean severity score by all patients stratified by gender and age. ANOVA test was used to evaluate the differences in symptom severity between the subgroups

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Patient Characteristics | | ESAS symptoms | | | | | | | | |
| Nausea | Shortness  of Breath | Lack  of Appetite | Pain | Drowsiness | Tiredness | Depression | Anxiety | Well-being |
| Mean ± SD | | | | | | | | |
| Gender | Male | 0.7±1.5 | 1.6±2.1 | 1.5±2.3 | 1.6±2.2 | 1.8±2.2 | 2.7±2.5 | 1.3±2.0 | 1.6±2.3 | 2.3±2.3 |
| Female | 0.6±1.5 | 1.2±2.0 | 1.4±2.2 | 1.6±2.2 | 1.7±2.2 | 2.8±2.5 | 1.4±2.1 | 2.0±2.4 | 2.4±2.3 |
| ANOVA | df | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| F | 80.7 | 2052.2 | 103.0 | 6.3 | 160.6 | 57.7 | 70.6 | 1061.0 | 64.8 |
| *p-value* | <0.01 | <0.01 | <0.01 | 0.012 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |
|  |  |  | | | | | | | | |
| Age (years) | 17-35 | 0.7±1.5 | 0.6±1.3 | 1.1±2.0 | 1.2±1.9 | 1.7±2.0 | 2.5±2.3 | 1.3±1.9 | 2.0±2.3 | 2.2±2.1 |
| 36-55 | 0.7±1.5 | 1.0±1.8 | 1.3±2.1 | 1.7±2.1 | 1.6±2.2 | 2.6±2.4 | 1.5±2.1 | 2.0±2.4 | 2.3±2.2 |
| 56-75 | 0.7±1.5 | 1.4±2.1 | 1.4±2.3 | 1.6±2.2 | 1.7±2.2 | 2.6±2.4 | 1.4±2.0 | 1.8±2.3 | 2.3±2.3 |
| 76-102 | 0.6±1.4 | 1.7±2.4 | 1.6±2.5 | 1.6±2.3 | 1.9±2.4 | 3.0±2.7 | 1.3±2.1 | 1.8±2.3 | 2.5±2.4 |
| ANOVA | df | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| F | 77.9 | 1132.0 | 211.2 | 74.3 | 173.0 | 315.0 | 45.8 | 118.1 | 127.1 |
| *p-value* | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |

ESAS=Edmonton Symptom Assessment System. SD=Standard Deviation. Mild severity includes scores from 1-3, moderate severity from 4-6, and high severity from 7-10.

**Table 4b:** ESAS symptoms mean severity score by all patients stratified by primary disease sites. ANOVA test was used to evaluate the differences in symptom severity between the primary disease site subgroups

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Primary Disease Site | ESAS symptoms | | | | | | | | |
| Nausea | Shortness  of Breath | Lack of  Appetite | Pain | Drowsiness | Tiredness | Depression | Anxiety | Well-being |
| Mean ± SD | | | | | | | | |
| Primary Disease Site | Breast | 0.4±1.2 | 0.9±1.6 | 1.0±1.9 | 1.4±2.0 | 1.4±2.0 | 2.4±2.3 | 1.3±1.9 | 1.8±2.2 | 2.0±2.1 |
| CNS | 0.7±1.6 | 1.2±2.0 | 1.4±2.4 | 1.2±1.8 | 2.3±2.6 | 3.1±2.9 | 1.8±2.4 | 2.4±2.8 | 2.5±2.4 |
| Endocrine | 0.8±1.3 | 1.1±1.4 | 1.4±1.9 | 2.0±2.0 | 1.4±2.1 | 2.3±2.2 | 1.4±1.6 | 1.2±1.6 | 1.8±2.0 |
| GI | 0.9±1.7 | 1.1±1.9 | 2.0±2.6 | 1.7±2.2 | 1.8±2.2 | 2.8±2.4 | 1.5±2.1 | 1.9±2.3 | 2.5±2.3 |
| GU | 0.6±1.4 | 1.2±2.0 | 1.2±2.1 | 1.5±2.2 | 1.6±2.2 | 2.5±2.5 | 1.2±2.0 | 1.5±2.1 | 2.0±2.3 |
| GYN | 0.8±1.7 | 1.2±2.0 | 1.5±2.3 | 1.5±2.2 | 1.8±2.3 | 2.8±2.6 | 1.4±2.1 | 2.0±2.4 | 2.5±2.4 |
| Haematology | 0.6±1.4 | 1.5±2.2 | 1.3±2.2 | 1.5±2.2 | 1.8±2.3 | 2.8±2.6 | 1.3±2.1 | 1.7±2.2 | 2.4±2.3 |
| Head and Neck | 1.6±2.3 | 2.2±2.8 | 3.8±3.5 | 2.9±2.7 | 3.0±2.8 | 4.1±2.8 | 2.8±3.0 | 3.3±2.9 | 3.9±2.8 |
| Lung | 0.9±1.7 | 2.9±2.7 | 2.1±2.7 | 2.1±2.5 | 2.4±2.5 | 3.4±2.6 | 1.7±2.3 | 2.2±2.5 | 3.0±2.5 |
| Sarcoma | 0.9±1.8 | 1.8±2.4 | 2.1±2.6 | 1.8±2.3 | 2.2±2.3 | 3.2±2.5 | 1.6±2.1 | 2.2±2.3 | 2.9±2.3 |
| Skin | 0.5±1.3 | 1.1±1.8 | 1.1±2.0 | 1.4±2.0 | 1.6±2.1 | 2.4±2.4 | 1.2±1.9 | 1.8±2.3 | 2.1±2.2 |
| Primary Unknown | 1.0±1.9 | 2.1±2.5 | 2.7±2.9 | 2.8±2.7 | 3.0±2.9 | 3.9±3.0 | 2.2±2.6 | 2.8±2.8 | 3.4±2.7 |
| Other Cancers | 1.3±1.8 | 2.3±2.2 | 2.4±2.5 | 2.5±2.4 | 2.9±2.6 | 3.9±2.7 | 2.9±2.6 | 3.4±3.0 | 3.7±2.6 |
| ANOVA | df | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| F | 302.2 | 1560.8 | 673.9 | 224.8 | 391.8 | 338.2 | 127.1 | 163.9 | 357.2 |
| *p-value* | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 |

ESAS=Edmonton Symptom Assessment System. SD=Standard Deviation. Mild severity includes scores from 1-3, moderate severity from 4-7, and high severity from 8-10.

**Table 6a:** Mean ESAS total distress score, ESAS physical distress sub-score and ESAS psychological distress sub-score stratified by gender and age. The ESAS total symptom distress score is stratified into TOT-low (0-8, data not shown), TOT-mild (9-35), TOT-moderate (36-62) and TOT-severe (63-90); the physical sub-scores is stratified into PHY-low (0-5, data not shown), PHY-mild (6-23), PHY-moderate (24-41) and PHY-severe (42-60) and the psychological sub-scores is stratified into PSY-low (0-1, data not shown), PSY-mild (2-7), PSY-moderate (8-13 ) and PSY-severe (14-20).

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Patient  Characteristics | | **ESAS Total Distress Score** | | | **ESAS Physical Distress Sub-score** | | | **ESAS Psychological Distress Sub-score** | | |
| TOT-Mild  9-35 | TOT-Moderate  36-62 | TOT-Severe  63-90 | PHY-Mild  6-23 | PHY-Moderate  24-41 | PHY-Severe  42-60 | PSY-Mild  2-7 | PSY-Moderate  8-13 | PSY-Severe  14-20 |
| Mean ± SD | | | | | | | | |
| Gender | Male | 18.9±7.4 | 44.9±7.0 | 69.4±5.9 | 12.4±4.9 | 29.9±4.7 | 46.1±3.9 | 3.9±1.6 | 9.9±1.6 | 15.8±1.8 |
| Female | 18.8±7.4 | 44.7±6.9 | 69.4±5.8 | 12.2±4.9 | 29.8±4.7 | 46.4±3.9 | 3.8±1.7 | 9.9±1.6 | 16.0±1.9 |
| ANOVA | df | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| F | 5.3 | 4.8 | 0.04 | 26.5 | 5.1 | 2.5 | 6.0 | 1.4 | 16.3 |
| *p-value­* | 0.02 | 0.03 | 0.84 | <0.01 | 0.02 | 0.11 | 0.02 | 0.23 | <0.01 |
|  |  |  |  |  |  |  |  |  |  |  |
| Age (years) | 17-35 | 18.2±7.0 | 44.7±7.1 | 66.3±5.3 | 12.0±4.6 | 29.7±4.6 | 44.2±2.0 | 3.8±1.6 | 9.8±1.6 | 15.7±1.9 |
| 36-55 | 18.5±7.3 | 44.9±7.1 | 69.2±5.8 | 12.0±4.8 | 29.9±4.6 | 46.3±3.9 | 3.9±1.7 | 9.8±1.6 | 16.0±1.9 |
| 56-75 | 18.9±7.4 | 44.6±6.9 | 69.5±6.0 | 12.4±4.9 | 29.8±4.7 | 46.4±4.0 | 3.8±1.7 | 9.8±1.6 | 15.9±1.9 |
| 76-102 | 18.9±7.5 | 45.0±7.0 | 69.4±5.5 | 12.4±4.9 | 29.8±4.7 | 46.1±3.8 | 3.8±1.6 | 9.9±1.6 | 15.8±1.7 |
| ANOVA | df | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| F | 22.1 | 5.1 | 1.1 | 32.5 | 0.1 | 1.1 | 6.0 | 2.2 | 5.1 |
| *p-value­* | <0.01 | <0.01 | 0.37 | <0.01 | 0.96 | 0.36 | <0.01 | 0.09 | <0.01 |

ESAS=Edmonton Symptom Assessment System.

**Table 6b:** Mean ESAS total distress score, ESAS physical distress sub-score and ESAS psychological distress sub-score stratified by primary disease site. The ESAS total symptom distress score is stratified into TOT-low (0-8, data not shown), TOT-mild (9-35), TOT-moderate (36-62) and TOT-severe (63-90); the physical sub-scores is stratified into PHY-low (0-5, data not shown), PHY-mild (6-23), PHY-moderate (24-41) and PHY-severe (42-60) and the psychological sub-scores is stratified into PSY-low (0-1, data not shown), PSY-mild (2-7), PSY-moderate (8-13 ) and PSY-severe (14-20).

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **ESAS Total Distress Score** | | | **ESAS Physical Distress Sub-score** | | | **ESAS Psychological Distress Sub-score** | | |
| Primary Disease Site | TOT-Mild  9-35 | TOT-Moderate  36-62 | TOT-Severe  63-90 | PHY-Mild  6-23 | PHY-Moderate  24-41 | PHY-Severe  42-60 | PSY-Mild  2-7 | PSY-Moderate  8-13 | PSY-Severe  14-20 |
| Breast | 18.1±7.1 | 44.1±6.7 | 68.4±5.4 | 11.7±4.7 | 29.4±4.6 | 45.7±3.6 | 3.8±1.6 | 9.8±1.6 | 15.8±1.7 |
| Central Nervous System | 19.1±7.8 | 45.0±7.2 | 68.3±5.0 | 12.4±5.1 | 29.8±4.7 | 44.0±2.1 | 3.9±1.6 | 10.2±1.6 | 16.1±2.0 |
| Endocrine | 17.2±6.1 | 44.0±7.5 | 66.0±0.0 | 10.5±4.0 | 30.6±5.4 | 42.0±0.0 | 4.0±1.4 | 8.8±1.1 | 15.3±0.6 |
| Gastrointestinal | 19.2±7.4 | 44.7±6.9 | 70.0±6.0 | 12.5±4.9 | 29.9±4.6 | 46.6±4.1 | 3.9±1.7 | 9.9±1.6 | 15.9±2.0 |
| Genitourinary | 18.8±7.4 | 45.2±7.1 | 68.8±6.9 | 12.2±4.9 | 29.9±4.7 | 46.0±4.1 | 3.8±1.6 | 9.9±1.6 | 15.7±1.8 |
| Gynaecological | 19.0±7.5 | 45.3±7.0 | 68.4±5.8 | 12.8±5.0 | 29.9±4.7 | 45.5±3.3 | 3.8±1.7 | 10.0±1.7 | 15.7±1.8 |
| Haematology | 18.8±7.5 | 44.9±7.0 | 69.8±6.3 | 12.3±4.9 | 29.7±4.6 | 46.4±3.9 | 3.8±1.6 | 9.8±1.6 | 16.1±1.9 |
| Head and Neck | 22.3±7.9 | 46.7±7.9 | 68.2±4.9 | 15.1±5.1 | 31.5±5.2 | 45.5±3.7 | 4.5±1.7 | 10.1±1.6 | 16.2±1.8 |
| Lung | 20.1±7.5 | 44.9±7.0 | 69.6±5.5 | 13.3±5.1 | 30.2±4.8 | 46.6±3.9 | 3.9±1.7 | 9.9±1.6 | 15.9±1.9 |
| Sarcoma | 19.4±7.4 | 45.7±7.0 | 69.1±5.4 | 12.5±4.8 | 30.4±4.8 | 46.8±4.2 | 4.0±1.7 | 9.7±1.5 | 15.7±1.4 |
| Skin | 18.4±7.3 | 44.1±7.0 | 71.4±5.9 | 11.9±4.8 | 29.0±4.6 | 46.0±3.5 | 3.7±1.6 | 10.1±1.8 | 15.8±1.9 |
| Primary Unknown | 19.9±7.4 | 46.0±7.0 | 66.1±3.1 | 13.7±5.2 | 30.6±4.8 | 44.9±3.8 | 4.0±1.7 | 10.0±1.5 | 16.6±2.1 |
| Other Cancers | 23.2±7.7 | 43.9±6.4 | 65±0.0 | 13.6±4.9 | 29.8±4.0 | - | 5.1±1.5 | 10.5±1.7 | 15.2±1.1 |
| All | 18.8±7.4 | 44.8±6.9 | 69.4±5.9 | 12.3±4.9 | 29.8±4.7 | 46.3±3.9 | 3.8±1.6 | 9.9±1.6 | 15.9±1.9 |
| ANOVA | | | | | | | | | |
| df | 12 | 12 | 12 | 12 | 12 | 11 | 12 | 12 | 12 |
| F | 66.2 | 6.2 | 2.4 | 95.0 | 8.3 | 1.9 | 15.3 | 4.1 | 3.1 |
| *p-value* | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | 0.04 | <0.01 | <0.01 | <0.01 |

ESAS=Edmonton Symptom Assessment System.